Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. (Z0105)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00354822|
Recruitment Status : Terminated (Inability to recruit in time a sufficient number of patients)
First Posted : July 20, 2006
Last Update Posted : September 18, 2009
Pilot multicentre, open label study with the aim to evaluate antitumor activity in term of the sum of complete and partial response (O.R.R.) of chemotherapy (cyclophosphamide and fludarabine) and rituximab, followed by zevalin radioimmunotherapy and response duration (Time to relapse or progression)and to evaluate the safety of the treatment as acute and late toxicity.
Secondary objective is to evaluate the overall survival (OS) and the event-free survival (EFS).
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma, Non-Hodgkin||Drug: Zevalin||Phase 2|
- Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts>150x10^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
- Standard dose chemotherapy consisting of cyclophosphamide, fludarabine and rituximab given every 28 days up to the best response (maximum 6 courses).
- A prophylaxis for pneumocystis carinii as well as for herpes zoster are needed during treatment.
Main parameters of activity: activity of Yttrium-90 (90Y) ibritumomab tiuxetan after cyclophosphamide, fludarabine and rituximab combination.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study for Use of Oral Fludarabine Plus Cyclophosphamide and Rituximab Followed by Zevalin as Front-Line Treatment for Non-Follicular Indolent Lymphomas.|
|Study Start Date :||August 2005|
|Estimated Primary Completion Date :||August 2009|
|Actual Study Completion Date :||August 2009|
- Drug: Zevalin
Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts>150x10^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
- achievement and duration of complete or partial reduction of lymphnodes six weeks after the end of treatment with zevalin [ Time Frame: 2 years ]
- overall and event free survival [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00354822
|USC Ematologia Ospedali Riuniti di Bergamo|
|Bergamo, BG, Italy, 24128|
|U.O. Ematologia Ospedali Civili Brescia|
|Brescia, BS, Italy|
|Medicina Nucleare ed Oncologia Medica AOU Policlinico Universitario di Messina|
|Messina, ME, Italy, 98125|
|Istituto per la Ricerca e la Cura del Cancro IRCC|
|Candiolo, TO, Italy, 10060|
|SC Ematologia 2 ASO S. Giovanni Battista|
|Torino, TO, Italy|
|U.O. Ematologia Ospedale Cà Foncello|
|Treviso, TV, Italy, 31100|
|Principal Investigator:||Cortelazzo Sergio, MD||Ospedale Centrale di Bolzano (Italy)|